CARMAT (FR0010907956, ALCAR), designer and developer of the world’s most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from advanced biventricular heart failure (the “Company” or “CARMAT”), provides an update on Aeson® artificial heart’s uptake as a bridge to transplant in Europe. Growing adoption of Aeson® as a bridge-to-transplant solution in Europe By the end of October 2024, 30 patients had successfully undergone heart transplant after being supported by the...